Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.68 |
| ▸ | FAP | Q12884 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Diphosphate SCHEMBL29395812 | 0.94 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| Tenofovir Diphosphate SCHEMBL14354588 | 0.94 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| Tenofovir Diphosphate SCHEMBL29466912 | 0.94 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| Tenofovir Diphosphate SCHEMBL24809661 | 0.94 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| SCHEMBL20313254 | 0.92 | CYP3A4 (0.74) | CYP3A4CYP2D6FAP | |
| SCHEMBL24809662 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2D6FAP | |
| SCHEMBL14440381 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2D6FAP | |
| SCHEMBL13394165 | 0.91 | CYP3A4 (0.75) | CYP3A4CYP2D6FAP | |
| SCHEMBL20321881 | 0.90 | CYP3A4 (0.71) | CYP3A4CYP2D6FAP | |
| SCHEMBL21986443 | 0.88 | CYP3A4 (0.79) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262365-A1 | ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20170326146-A1 | METHODS OF TREATING HEPATITIS B INFECTIONS AND RELATED DOSAGE REGIMES | CONTRAVIR PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326146-A1 | METHODS OF TREATING HEPATITIS B INFECTIONS AND RELATED DOSAGE REGIMES | SLC10A1, HAVCR2, HLA-B | CYP3A4 62/4885CYP2D6 29/4885FAP 991/4885 |
| US-20190262365-A1 | ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS | PNP, TYMP, DUT | CYP3A4 1082/4885CYP2D6 1883/4885FAP 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.